I am not sure quarterly results can justify the run - it more than doubled in 6 months!
Maybe market expects some type of acquisition-reorganization?
Of course, RAD is too deep in debt, but---let us hope for sudden news.
Markets always look out 18-24 months ahead. Look at RAD's comps (P/S, P/E ratios) relative to peers. This is a grossly misunderstood and misvalued stock. Even if they can hold top line flat (or +/- 1%) but improve on operational costs, EPS will continue to show a positive trend. And with all this debate on whether Europe is truly recovering, whether China is back, Egypt is going to melt-down you think it really affects the domestic prescriptions business? Macro trends will favor this sector (CVS/WAG/RAD) for a while with baby boomers retiring, ACA kicking in and $40B of patented drug sales moving to generics (with higher gross margins). RAD's the most undervalued of the pack...